viewRevive Therapeutics

Revive Therapeutics: Analyst sees 'substantial upside potential' as key assets move towards clinic

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a well-established safety profile having been prescribed for arthritis for more than 30 years. Revive Therapeutics has made an IND filing concerning the use of BUC to treat COVID-19 with intellectual property around infectious diseases.


Click here to read Ed Stacey's initiation note on Revive Therapeutics

Quick facts: Revive Therapeutics

Price: 0.42 CAD

Market: CSE
Market Cap: $99.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...


Revive Therapeutics updates on potential COVID-19 treatment, and its oral...

Revive Therapeutics Ltd. (CSE: RVV) (OTCMKTS: RVVTF) CEO Michael Frank and Psilocin Pharma Founder Derrick Welsh explain to Proactive how the Toronto-based company is currently advancing to a Phase 3 clinical trial to treat the coronavirus with a rheumatoid arthritis therapy, in addition to its...

on 6/5/20

2 min read